IgG4相关性疾病患者恶性肿瘤患病率增加:对临床诊疗的启示
该回顾性研究纳入210例IgG4相关性疾病(IgG4-RD)患者,比较其与意大利人群的癌症患病率。37/210例(18%)在IgG4-RD诊断前后发生癌症,标化发病比(SIR)为2.54(P=0.007),男性SIR为2.78(P=0.005),女性SIR为1.15(P>0.05)。作者认为IgG4-RD患者癌症患病率较意大利人群增加,并建议在IgG4-RD诊断后前36个月内密切监测。
要点
- 210例IgG4-RD患者中37例(18%)在诊断前后发生癌症。
- IgG4-RD患者癌症SIR为2.54,高于意大利一般人群(P=0.007)。
- 作者建议IgG4-RD诊断后前36个月内密切监测。
核心结论
- IgG4-RD患者癌症患病率较意大利人群增加,机制上提示可能存在副肿瘤关联,作者建议在IgG4-RD诊断后前36个月内密切监测。
研究设计与样本
- 回顾性研究纳入210例IgG4-RD患者,分析IgG4-RD表型、临床和血清学变量,并使用世界卫生组织全球癌症观察站(GCO)登记数据及意大利人群2015-2020年5年有限持续时间患病率计算标化发病比(SIR)。
主要发现
- 37/210例患者(18%)在IgG4-RD诊断前或诊断后发生癌症。
- 胰腺胆管型IgG4-RD中更常观察到实体瘤和血液系统肿瘤。
- IgG4-RD患者恶性肿瘤SIR为2.54,高于意大利一般人群(P=0.007)。
- 男性SIR为2.78(P=0.005),女性SIR为1.15(P>0.05)。
- 32例恶性肿瘤在IgG4-RD诊断前诊断,16例在诊断后诊断;从IgG4-RD到癌症的间隔短于从癌症到IgG4-RD的间隔;IgG4-RD后发生的大多数肿瘤在IgG4-RD诊断后36个月内出现。
临床怎么用
- 作者建议在IgG4-RD诊断后前36个月内密切监测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The association between cancer and IgG4-related disease (IgG4-RD) is evolving. The primary aim of this study was to investigate the prevalence of malignancies in IgG4-RD. The secondary aim was to describe the epidemiological and clinical characteristics of IgG4-RD patients with a history of cancer. METHODS: Two hundred and ten patients with IgG4-RD were included in this retrospective study. IgG4-RD phenotypes, clinical and serological variables were analysed. The prevalence of cancer in IgG4-RD was compared with that in the Italian population using the registry of the Global Cancer Observatory (GCO) of the World Health Organization. The Standardized Incidence Ratio (SIR) for cancer in IgG4-RD was obtained based on the 5-year Limited Duration Prevalence (2015-2020) of tumours in the Italian population. RESULTS: Thirty-seven/210 patients (18%) developed cancer before or after the diagnosis of IgG4-RD. Solid and haematologic tumours were more frequently observed in pancreato-biliary IgG4-RD. The SIR for malignancy in IgG4-RD patients was 2.54 higher than the general Italian population (P = 0.007). The SIR was 2.78 higher for males (P = 0.005) and 1.15 higher for females (P > 0.05). Thirty-two malignancies were diagnosed before and 16 after IgG4-RD diagnosis. Interval 'from IgG4-RD to cancer' was shorter than that 'from cancer to IgG4-RD'. Most tumours occurring after IgG4-RD developed within 36 months from diagnosis of IgG4-RD. CONCLUSIONS: The prevalence of cancer in patients with IgG4-RD is increased compared with the Italian population and mechanistically suggests a possible paraneoplastic association. Close surveillance is warranted for the first 36 months after IgG4-RD diagnosis.
引用
- Keller-Sarmiento L, Viapiana N, Lanzillotta M, et al. Increased prevalence of malignancies in patients with IgG4-related disease: implications for clinical care. Rheumatology (Oxford). 2025. PMID: 38696755. doi:10.1093/rheumatology/keae243
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。